Israel Englander Biocryst Pharmaceuticals Inc Call Options Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $649,333 - $880,297	101,300 New	101,300 $769,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $1.91 Million - $2.99 Million	-390,600 Reduced 66.0%	201,200 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $2.44 Million - $3.32 Million	490,900 Added 486.52%	591,800 $3.54 Million
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $963,264 - $1.22 Million	-138,400 Reduced 57.84%	100,900 $710,000
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $1.1 Million - $1.64 Million	138,600 Added 137.64%	239,300 $2 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $1.06 Million - $1.43 Million	100,700 New	100,700 $1.16 Million

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.